Signaturefd LLC Sells 2,372 Shares of Fresenius Medical Care AG (NYSE:FMS)

Signaturefd LLC lessened its stake in Fresenius Medical Care AG (NYSE:FMS) by 27.2% during the 3rd quarter, Holdings Channel.com reports. The firm owned 6,341 shares of the company’s stock after selling 2,372 shares during the quarter. Signaturefd LLC’s holdings in Fresenius Medical Care were worth $135,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Castleview Partners LLC boosted its holdings in shares of Fresenius Medical Care by 35.9% in the 3rd quarter. Castleview Partners LLC now owns 17,286 shares of the company’s stock valued at $368,000 after buying an additional 4,571 shares in the last quarter. Blue Trust Inc. boosted its stake in Fresenius Medical Care by 1,060.9% in the third quarter. Blue Trust Inc. now owns 12,863 shares of the company’s stock valued at $274,000 after acquiring an additional 11,755 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in Fresenius Medical Care in the third quarter worth $112,000. GAMMA Investing LLC increased its position in shares of Fresenius Medical Care by 50.4% during the third quarter. GAMMA Investing LLC now owns 4,998 shares of the company’s stock worth $106,000 after purchasing an additional 1,675 shares in the last quarter. Finally, Kimelman & Baird LLC purchased a new stake in shares of Fresenius Medical Care during the 2nd quarter valued at $186,000. 8.25% of the stock is currently owned by institutional investors.

Fresenius Medical Care Price Performance

Shares of FMS opened at $20.93 on Monday. The firm has a market capitalization of $12.28 billion, a PE ratio of 21.58, a price-to-earnings-growth ratio of 1.11 and a beta of 0.91. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.46 and a quick ratio of 1.09. The company’s fifty day moving average price is $20.24 and its 200-day moving average price is $20.15. Fresenius Medical Care AG has a 1-year low of $16.37 and a 1-year high of $22.76.

Fresenius Medical Care (NYSE:FMS) last announced its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.38. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. The business had revenue of $5.13 billion for the quarter, compared to analyst estimates of $5.28 billion. On average, equities research analysts predict that Fresenius Medical Care AG will post 1.52 EPS for the current year.

Wall Street Analysts Forecast Growth

FMS has been the topic of several research analyst reports. Truist Financial boosted their target price on Fresenius Medical Care from $22.00 to $23.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. StockNews.com initiated coverage on Fresenius Medical Care in a research note on Tuesday, October 8th. They set a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $23.00.

Fresenius Medical Care Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.